Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its generic version of Concor, which contains bisoprolol and amlodipine, a compound preparation used as an alternative therapy for hypertension. The approval signifies that Easton’s version has also passed the generic quality consistency evaluation (GQCE), meeting the same high standards as the original product.
Merck KGaA, the originator of Concor, first received approval in the European Union (EU) in February 2011 and later in China in May 2021. The drug was subsequently awarded reimbursement as a Category B drug on the National Reimbursement Drug List (NRDL). Easton’s generic version, filed as a Category 4 chemical drug, is the first of its kind to be granted marketing approval with GQCE status in China. – Flcube.com
